Trade Editas Medicine - EDIT CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.06 | ||||||||
|
Long position overnight fee
Long position overnight fee
Go to platform | -0.026179% | ||||||||
|
Short position overnight fee
Short position overnight fee
Go to platform | 0.003957% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 5.43 |
| Open | 5.48 |
| 1-Year Change | -32.68% |
| Day's Range | 5.26 - 5.48 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Apr 24, 2024 | 5.33 | -0.13 | -2.38% | 5.46 | 5.54 | 5.25 |
| Apr 23, 2024 | 5.43 | -0.09 | -1.63% | 5.52 | 5.88 | 5.43 |
| Apr 22, 2024 | 5.58 | 0.03 | 0.54% | 5.55 | 5.76 | 5.35 |
| Apr 19, 2024 | 5.47 | -0.01 | -0.18% | 5.48 | 5.65 | 5.25 |
| Apr 18, 2024 | 5.53 | 0.02 | 0.36% | 5.51 | 5.64 | 5.48 |
| Apr 17, 2024 | 5.59 | -0.23 | -3.95% | 5.82 | 5.89 | 5.57 |
| Apr 16, 2024 | 5.82 | -0.09 | -1.52% | 5.91 | 5.99 | 5.82 |
| Apr 15, 2024 | 6.04 | -0.13 | -2.11% | 6.17 | 6.25 | 5.94 |
| Apr 12, 2024 | 6.18 | -0.25 | -3.89% | 6.43 | 6.51 | 6.10 |
| Apr 11, 2024 | 6.56 | -0.09 | -1.35% | 6.65 | 6.65 | 6.42 |
| Apr 10, 2024 | 6.59 | -0.15 | -2.23% | 6.74 | 6.74 | 6.51 |
| Apr 9, 2024 | 7.00 | 0.36 | 5.42% | 6.64 | 7.00 | 6.61 |
| Apr 8, 2024 | 6.69 | 0.02 | 0.30% | 6.67 | 6.83 | 6.65 |
| Apr 5, 2024 | 6.68 | 0.05 | 0.75% | 6.63 | 6.81 | 6.59 |
| Apr 4, 2024 | 6.76 | -0.08 | -1.17% | 6.84 | 7.06 | 6.74 |
| Apr 3, 2024 | 6.82 | 0.04 | 0.59% | 6.78 | 7.00 | 6.61 |
| Apr 2, 2024 | 6.84 | -0.20 | -2.84% | 7.04 | 7.11 | 6.83 |
| Apr 1, 2024 | 7.25 | -0.07 | -0.96% | 7.32 | 7.35 | 7.11 |
| Mar 28, 2024 | 7.37 | -0.02 | -0.27% | 7.39 | 7.47 | 7.33 |
| Mar 27, 2024 | 7.40 | 0.13 | 1.79% | 7.27 | 7.50 | 7.15 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Editas Medicine Company profile
Editas Medicine, Inc. operates as a clinical stage genome editing company. The company focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary genome editing platform based on CRISPR technology to target genetically addressable diseases and therapeutic areas. The company develops EDIT-101 for Leber Congenital Amaurosis type 10, a genetic form of vision loss that leads to blindness in childhood. It also develops other therapies for eye diseases, such as Usher Syndrome 2A, which is a form of retinitis pigmentosa that also includes hearing loss; Retinitis Pigmentosa, a progressive form of retinal degeneration; and Herpes Simplex Virus 1 that causes lifelong infections leading to ocular and oral disease. In addition, the company develops hematopoietic stem cells for treating sickle cell disease and beta thalassemia. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; a strategic alliance and option agreement with Allergan Pharmaceuticals International Limited to discover, develop, and commercialize new gene editing medicines for a range of ocular disorders; and a strategic research collaboration and cross-licensing agreement with BlueRock Therapeutics to combine their respective genome editing and cell therapy technologies to discover, develop, and manufacture engineered cell medicines. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.| Industry: | Biotechnology & Medical Research (NEC) |
11 Hurley St
CAMBRIDGE
MASSACHUSETTS 02141-2110
US
News
We’re partnering with Newsquawk
Filter out the noise and focus on the news that matters.
08:32, 23 April 2024
US Earnings Season: Tesla, Alphabet, Meta Platforms and Microsoft
The first lot of Wall Street’s mega-cap tech companies report in the coming week. We preview what to expect from Tesla, Alphabet, Meta, and Microsoft’s quarterly results.
15:56, 22 April 2024
Gold price in 2024: geopolitical tensions and rate-cut expectations keep XAU/USD supported
Investors are keeping a close eye on gold as the conflict in the Middle East escalates with a possibility of a full-scale regional war in the area.
07:56, 17 April 2024
US Earnings Season : JP Morgan, Citigroup, Wells Fargo
The first major US banks report quarterly earnings on Friday, April 12th, 2024. We preview what to expect from JP Morgan, Citigroup, and Wells Fargo's quarterly numbers.
16:03, 11 April 2024
Reserve Bank of New Zealand Preview: Rates expected to remain on hold as inflation fight continues
The Reserve Bank of New Zealand (RBNZ) meets on Wednesday, April 10, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.
09:22, 11 April 2024
US CPI Preview: US inflation expected to grind lower amid fears about sticky prices
US CPI data is released on Wednesday, 10 April. We preview what to expect from the data, how it could influence US Federal Reserve policy, and analyse the NASDAQ (US Tech 100).
15:11, 9 April 2024
How escalating geopolitical tensions are impacting oil markets
The bullish momentum in oil prices remains strong as escalating geopolitical tensions raise concerns about supply.
13:34, 4 April 2024People also watch
Still looking for a broker you can trust?
Join the 610,000+ traders worldwide that chose to trade with Capital.com